Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial

BACKGROUND: Patient-reported outcomes (PROs) can provide important information about treatment tolerability in HIV-1-infected patients. OBJECTIVE: The aim of this study was to evaluate PROs following switching from a boosted protease inhibitor-based regimen to the single-tablet regimen (STR) of rilp...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunetta, Jason, Moreno Guillén, Santiago, Antinori, Andrea, Yeni, Patrick, Wade, Barbara, Johnson, Margaret, Shalit, Peter, Ebrahimi, Ramin, Johnson, Bethsheba, Walker, Ivan, De-Oertel, Shampa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445257/
https://www.ncbi.nlm.nih.gov/pubmed/25808940
http://dx.doi.org/10.1007/s40271-015-0123-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445257/
https://www.ncbi.nlm.nih.gov/pubmed/25808940
http://dx.doi.org/10.1007/s40271-015-0123-2

Ejemplares similares